NCCN 2024 Prostate Cancer Guidelines Update by Maria Natalia Gandur Quiroga
Maria Natalia Gandur Quiroga shared a post on X:
“NCCN 2024 Prostate Cancer Guidelines Update.
- Major updates focus on the management of progressive M0 CSPC post-maximal pelvic therapy.
- Introduction of Enzalutamide, with or without Leuprolide, for specific high-risk cases based on the EMBARK trial.
- Emphasis on stringent risk stratification and monitoring, highlighting PSA doubling time as crucial.
Historical Context and New Studies:
- Discussion includes significant past studies like the Pound and Freedland et al., guiding current recommendations.
- New data from the EMBARK trial leads to the consideration of Enzalutamide in treatment protocols.
Implications for Treatment Strategies:
- Updated guidelines suggest a shift from purely monitoring to proactive treatment in certain high-risk M0 CSPC patients.
- The importance of identifying rapid PSA doubling times to tailor aggressive management strategies.
Overall Impact:
- These guideline changes aim to enhance outcomes for prostate cancer patients with a high risk of progression.
- Continuing education for professionals on these updates is crucial for optimal patient care. NCCN2024 updates.”
Source: Maria Natalia Gandur Quiroga/X
Maria Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Instituto de Oncología Ángel H. Roffo in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors. She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023